OOIR: Observatory of International Research

Papers

(The H4-Index of Oncoimmunology is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors	105
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization	103
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	82
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	72
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction	71
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status	68
MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells	67
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition	64
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	62
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection	61
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors	60
Ferroptosis: friend or foe in cancer immunotherapy?	60
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer	57
STING is significantly increased in high-grade glioma with high risk of recurrence	51
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer	51
PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis	46
Correction	44
The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response	44
Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas	43
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition	42
IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response	42
CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage	42
Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates	41
Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response	41
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC	40

CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival	40
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence	39
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma	39
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 ⁺ T cells eradicates peritoneal metastases in mouse models	39
PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells	38
Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid	36
Reprogramming monocyte-derived macrophages through caspase inhibition	36
Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34	35
Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer	35
Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy	35
CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model	35